Document is current
Any future updates will be listed below
-
Authors
Bunse, Lukas https://orcid.org/0000-0002-4490-7574
Pusch, Stefan https://orcid.org/0000-0002-3407-4249
Bunse, Theresa
Sahm, Felix
Sanghvi, Khwab
Friedrich, Mirco
Alansary, Dalia
Sonner, Jana K.
Green, Edward
Deumelandt, Katrin
Kilian, Michael
Neftel, Cyril
Uhlig, Stefanie
Kessler, Tobias
von Landenberg, Anna
Berghoff, Anna S.
Marsh, Kelly
Steadman, Mya
Zhu, Dongwei
Nicolay, Brandon
Wiestler, Benedikt
Breckwoldt, Michael O.
Al-Ali, Ruslan
Karcher-Bausch, Simone
Bozza, Matthias
Oezen, Iris
Kramer, Magdalena
Meyer, Jochen
Habel, Antje
Eisel, Jessica
Poschet, Gernot
Weller, Michael
Preusser, Matthias
Nadji-Ohl, Minou
Thon, Niklas
Burger, Michael C.
Harter, Patrick N.
Ratliff, Miriam
Harbottle, Richard
Benner, Axel
Schrimpf, Daniel
Okun, Jürgen
Herold-Mende, Christel
Turcan, Sevin
Kaulfuss, Stefan
Hess‐Stumpp, Holger
Bieback, Karen
Cahill, Daniel P.
Plate, Karl H.
Hänggi, Daniel
Dorsch, Marion
Suvà, Mario L. https://orcid.org/0000-0001-9898-5351
Niemeyer, Barbara A.
von Deimling, Andreas
Wick, Wolfgang https://orcid.org/0000-0002-6171-634X
Platten, Michael
- License Information
-
More Information
Article History
Received: 16 February 2018
Accepted: 27 March 2018
First Online: 9 July 2018
Competing interests
: M.Pl., W.W., and T.B. are inventors on a patent application entitled ‘Means and methods for treating or diagnosing IDH1R132H mutant-positive cancers’ (WO 2013/102641 A1, PCT/EP2013/050048). S.P. and A.v.D. are eligible to royalties as co-inventors of BAY 1436032 and are patent holders of ‘Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG)’ (WO2013127997A1). This patent is under the administrative supervision of the DKFZ technology transfer office. K.M., M.S., D.Z., B.N., and M.D. are full-time employees of Agios. S.K. and H.H.S. are full-time employees of Bayer. The other authors declare no conflict of interest. Requests for materials should be addressed to m.platten@dkfz.de.
